

Press Cutting

Citigate
Dewe Rogerson

Client: Chi Med

Publication: BioCentury

Date: 6 November 2009

Hutchison China's HMPL-004 meets Phase IIb endpoint

Hutchison China MediTech Ltd. (LSE:HCM) said HMPL-004 met the primary endpoint of a significantly higher total clinical response vs. placebo at week eight in a Phase IIb trial to treat ulcerative colitis (64% vs. 44%, $p=0.006$). The double-blind, international trial enrolled 223 patients with mild to moderate UC. HMPL-004 is an inflammatory cytokine inhibitor. Hutchison China was up 16p to 186.5p on Thursday. [Back to top](#)